Skip to main content
NewslettersWatchlist

Astrazeneca Plc ADR(AZN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low186.18
Day High192.79
Open:187.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Astrazeneca Plc ADR

Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN)
Motley Fool
Better Artificial Intelligence Stock: IonQ vs. D-Wave Quantum
Tipranks
AstraZeneca Advances AZD5148: Early Safety Data Strengthens Its Infectious Disease Pipeline
Zacks Investment Research
Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
Tipranks
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Berenberg Bank Sticks to Their Buy Rating for AstraZeneca (AZN)
Tipranks
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
Tipranks
AstraZeneca’s AZD1163 Clears Early Safety Hurdle: What Phase I Completion Means for Investors
Tipranks
AstraZeneca’s AZD3974 Enters Early Human Testing: What Investors Should Watch
Tipranks
Bank of America Securities Initiates a Buy Rating on AstraZeneca (AZN)
Tipranks
AstraZeneca Halts Early Heart Drug Study: What It Means for AZN Investors
Tipranks
AstraZeneca Sharpens Andexanet Strategy With New Phase I Dosing Study
Tipranks
AstraZeneca Ends Early-Stage Ceralasertib Combo Study: What Investors Should Know
Tipranks
AstraZeneca Tests Capivasertib in Liver-Impaired Patients: What Investors Should Watch
Tipranks
TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
Zacks Investment Research
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: ATAI Life Sciences (ATAI), AstraZeneca (AZN)
Tipranks
AstraZeneca’s Real‑World Tezepelumab Study Completes in UK Severe Asthma Centers
Tipranks
AstraZeneca’s Real‑World Osimertinib Study in Australia: What Investors Should Watch
Zacks Investment Research
European ETFs in Spotlight Following Trump's Tariff Retreat at Davos
European ETFs in Spotlight Following Trump's Tariff Retreat at Davos
Zacks Investment Research
Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?
Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?
MarketBeat
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
MarketBeat.com
Zacks Investment Research
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Tipranks
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)
Tipranks
UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)
Tipranks
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
Tipranks
AstraZeneca’s Atuliflapon Asthma Trial Reaches Completion: What Investors Should Watch Next
Tipranks
AstraZeneca’s Imfinzi Post‑Marketing Study in Japan: What the Completed Safety Tracking Means for Investors
Motley Fool
The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company)

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.